DB:ENMN

Stock Analysis Report

Executive Summary

CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally.


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has CASI Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ENMN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.4%

ENMN

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

-37.7%

ENMN

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: ENMN underperformed the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: ENMN underperformed the German Market which returned 6.1% over the past year.


Shareholder returns

ENMNIndustryMarket
7 Day-8.4%-4.1%-5.7%
30 Day-32.0%-8.2%-5.7%
90 Day-37.9%-2.0%-3.6%
1 Year-37.7%-37.7%4.0%3.7%9.3%6.1%
3 Year36.2%36.2%38.2%36.7%8.9%-0.7%
5 Year32.9%32.9%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is CASI Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CASI Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

2.46x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ENMN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ENMN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ENMN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ENMN is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ENMN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ENMN is good value based on its PB Ratio (2.5x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is CASI Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

59.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENMN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: ENMN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ENMN's is expected to become profitable in the next 3 years.

Revenue vs Market: ENMN's revenue (47% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: ENMN's revenue (47% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ENMN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CASI Pharmaceuticals performed over the past 5 years?

-14.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ENMN is currently unprofitable.

Growing Profit Margin: ENMN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ENMN is unprofitable, and losses have increased over the past 5 years at a rate of -14.7% per year.

Accelerating Growth: Unable to compare ENMN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENMN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: ENMN has a negative Return on Equity (-42%), as it is currently unprofitable.


Next Steps

Financial Health

How is CASI Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ENMN's short term assets ($73.4M) exceed its short term liabilities ($6.9M).

Long Term Liabilities: ENMN's short term assets ($73.4M) exceed its long term liabilities ($1.3M).


Debt to Equity History and Analysis

Debt Level: ENMN is debt free.

Reducing Debt: ENMN has no debt compared to 5 years ago when its debt to equity ratio was 166%.


Balance Sheet

Inventory Level: ENMN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ENMN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ENMN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ENMN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -47% each year


Next Steps

Dividend

What is CASI Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ENMN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ENMN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENMN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENMN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ENMN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Wei-Wu He (54yo)

0.8yrs

Tenure

US$6,105,000

Compensation

Dr. Wei-Wu He, Ph.D. serves as Chairman and Chief Executive Officer at CASI Pharmaceuticals, Inc since April 2, 2019 and served as its Executive Chairman from February 23, 2018 until April 2, 2019. Dr. He  ...


Leadership Team

NamePositionTenureCompensationOwnership
Wei-Wu He
Chairman & CEO0.8yrsUS$6.11m0.86% $1.6m
Wei Zhang
President0.4yrsUS$5.20mno data
Cynthia Hu
COO, General Counsel & Secretary11.2yrsUS$467.10k0.11% $197.2k
Sara Capitelli
VP of Finance & Principal Accounting Officer9.1yrsUS$222.19kno data
James Goldschmidt
Senior Vice President of Business Development0.8yrsno datano data
Alexander Zukiwski
Chief Medical Officer2.8yrsUS$612.01kno data

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: ENMN's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Wei-Wu He
Chairman & CEO0.8yrsUS$6.11m0.86% $1.6m
Quan Zhou
Independent Director3.7yrsUS$300.50kno data
Ruijin Huang
Independent Director6.8yrsUS$300.50k0.00020% $363.1
Rajesh Shrotriya
Independent Director5.4yrsUS$212.85kno data
S. Eckhardt
Member of Scientific Advisory Board13.6yrsno datano data
Y. Wu
Independent Director6.8yrsUS$212.85kno data
Ghassan Abou-Alfa
Member of Clinical Advisory Board4.6yrsno datano data
Franklin Salisbury
Independent Director5.7yrsUS$212.85kno data
Robert Mayer
Member of Clinical Advisory Board4.6yrsno datano data

5.7yrs

Average Tenure

58yo

Average Age

Experienced Board: ENMN's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.3%.


Top Shareholders

Company Information

CASI Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CASI Pharmaceuticals, Inc.
  • Ticker: ENMN
  • Exchange: DB
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$197.510m
  • Listing Market Cap: US$181.551m
  • Shares outstanding: 96.35m
  • Website: https://www.casipharmaceuticals.com

Number of Employees


Location

  • CASI Pharmaceuticals, Inc.
  • 9620 Medical Center Drive
  • Suite 300
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CASINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 1996
ENMNDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1996

Biography

CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin’s lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/26 20:40
End of Day Share Price2020/02/26 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.